MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes

Table 6 MicroRNAs selected criteria for inclusion

MiRNA name	HCC	LC	Fold change	Log2 fold change	P value
hsa-miR-1	0.13	0.32	0.41	-1.29	0.168
hsa-miR-16	0.12	0.43	0.28	-1.84	0.001a
hsa-miR-21	4.21	3.82	1.10	0.14	0.801
hsa-miR-23b-3p	0.27	0.78	0.35	-1.51	0.001a
hsa-miR-26a	0.33	0.51	0.64	-0.64	0.009
hsa-miR-29a	0.54	0.42	1.29	0.37	0.001
hsa-miR-34-a	0.69	0.16	4.31	2.11	0.001a
hsa-miR-98	1.95	1.19	1.63	0.70	0.723
hsa-miR-122-5p	0.12	0.98	0.12	-3.06	0.001a
hsa-miR-125b-5p	0.01	0.05	0.20	-2.32	0.823
hsa-miR-127-3p	0.29	0.78	0.37	-1.43	0.059
hsa-miR-150-5p	2.16	0.78	2.78	1.48	0.071
hsa-miR-185-5p	0.21	0.88	0.24	-2.06	0.083
hsa-miR-198	0.09	0.29	0.31	-1.69	0.001a
hsa-miR-199a-3p	0.08	0.31	0.26	-1.94	0.001a
hsa-miR-221	9.40	3.31	2.84	1.51	0.001a
hsa-miR-224-5p	1.82	0.71	2.56	1.36	0.021
hsa-miR-494-3p	0.98	0.17	5.76	2.53	0.022
hsa-miR-877-5p	1.51	0.78	1.94	0.96	0.231
hsa-miR-4433b-3	1.52	0.45	3.38	1.76	0.072

Expression data is presented as average fold change = (2^-ΔΔCT) in the hepatocellular carcinoma group vs the liver cirrhosis group.

^aP < 0.005 with ± 1.5 log₂ fold expression change. HCC: Hepatocellular carcinoma; LC: Liver cirrhosis; miRNA: MicroRNA.